Three Circulating miRNAs Related to Non-Small-Cell Lung Cancer Progression: An Integrative Analysis of Their Biological Roles

Simple Summary Lung cancer, especially non-small-cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide. In this study, we explored three microRNAs (miRNAs) found in the blood that could potentially serve as biomarkers for monitoring the progression of lung cancer. Our analysis revealed that these miRNAs were significantly altered in cancerous lung tissues compared to normal tissues. Specifically, we identified hsa-miR-451a, hsa-miR-139-5p, and hsa-miR-126-5p as key players in the development of lung cancer, which may aid in its diagnosis and prognosis. These findings could enhance early detection and provide new therapeutic insights for NSCLC, ultimately improving patient care and public health outcomes.

• Publication year

  2025

• Venue

  Biology

• Publication date

  2025-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/biology14040399PMID 40282264PMCID 12024873
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• Dynamic interplay of microRNA in diseases and therapeutic

  2022cited by this paper
• KEGG for taxonomy-based analysis of pathways and genomes

  2022influential reference
• Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer

  2022cited by this paper
• LncPTSR Triggers Vascular Remodeling in Pulmonary Hypertension by Regulating [Ca2+]i in Pulmonary Arterial Smooth Muscle Cells.

  2022cited by this paper
• DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)

  2022influential reference
• Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer.

  2021cited by this paper
• Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

  2021cited by this paper
• Circulating miRNAs as Biomarker in Cancer.

  2020cited by this paper
• miRNA-based biomarkers, therapies, and resistance in Cancer

  2020cited by this paper
• Identifying circulating miRNA biomarkers for early diagnosis and monitoring of lung cancer.

  2020cited by this paper
• MicroRNA and Cardiovascular Diseases

  2020cited by this paper
• Identification of key microRNAs and hub genes in non‐small‐cell lung cancer using integrative bioinformatics and functional analyses

  2020cited by this paper
• Circulating miRNA analysis for cancer diagnostics and therapy.

  2020cited by this paper
• The Roles of MicroRNA in Lung Cancer

  2019cited by this paper
• The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients

  2019cited by this paper
• New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx

  2019cited by this paper
• Circulating Plasma miRNAs as Potential Biomarkers of Non–Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling

  2018influential reference
• Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification

  2017cited by this paper
• Circulating microRNA-422a is associated with lymphatic metastasis in lung cancer

  2017cited by this paper
• Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing

  2017cited by this paper
• GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

  2017cited by this paper
• miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor

  2016cited by this paper
• Communication by Extracellular Vesicles: Where We Are and Where We Need to Go.

  2016cited by this paper
• limma powers differential expression analyses for RNA-sequencing and microarray studies

  2015cited by this paper
• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression

  2014cited by this paper
• Tumor surveillance by circulating microRNAs: a hypothesis

  2014cited by this paper
• Stage and tissue-specific prognostic impact of miR-182 in NSCLC

  2014cited by this paper
• Circulating miRNAs: cell–cell communication function?

  2013cited by this paper
• Secreted microRNAs: a new form of intercellular communication.

  2012cited by this paper
• MicroRNA and Cardiovascular Diseases

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor

  2007cited by this paper
• MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B

  2007cited by this paper
• Impaired microRNA processing enhances cellular transformation and tumorigenesis

  2007cited by this paper
• MicroRNA expression profiles classify human cancers

  2005cited by this paper
• MicroRNAs: small RNAs with a big role in gene regulation

  2004cited by this paper

• Deciphering the structural dynamics of Argonaute (AGO)-mediated gene silencing of miR-21-5p, miR-221-3p, miR-126-3p, miR-34a-5p and their role as potential biomarkers in lung cancer.

  2025cites this paper
• Advances in the role of extracellular vesicles in circulating microRNA biomarker discovery for lung cancer

  2025cites this paper
• Prediction of miRNA-disease associations using a dual-channel contrastive model based on multi-source information fusion

  2025cites this paper
• Investigating therapeutic potential of Evodiamine by identifying differentially expressed genes in cisplatin resistance non-small cell lung cancer

  2025cites this paper